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E-selectin is an endothelial adhesion molecule that 
binds carbohydrate epitopes on leukocytes and has 
been implicated in a potential pathway of tumor 
metastasis . Keratinocyte cell lines express similar 
carbohydrate epitopes. one of which. sialyl Lewis X 
(SL-X) is a ligand for E-selectin and is also expressed 
by squamous cell carcinomas (SCC) ill sitl/ . The func-
tional role ofkeratinocyte selectinligands was inves-
tigated using a soluble E -selectin chima eric protein 
(pE-sel Ig) containing pig lectin-like and epidermal 
growth factor-like domains fused to human IgG. 
After incubation of keratinocyte cell lines (A431 and 
SVK14) and normal keratinocytes with pE- sel Ig. 
binding was quantified by flow cytometry. Frozen 
sections of SCC were overlaid with pE-sel Ig and 
binding was visualized iml11.unoenzymatically. Im-
munolabeling was undertaken using monoclonal an-
tibodies (CSLEX- l and HECA- 452). which label E-
selectin ligands including sialyl Lewis X. E -se1ectin 
T umor m etastas. is involves move. ment of malignant ce lls to sites of secondary tumor formation where these cells interact with endothelium and migrate into tissue to produce micrometastatic colonies (AI-be Ida , 1993). Some tumor cells possess a range of ceU 
surface adhesion molecules that may govern m etasta tic behavior. 
These include integrins , immunoglobulin gene superfamily mole-
cules, and cell surf.,ce C;lrbohydrates that act as ligands for selectins 
(Alb e lda, 1993; Hart and Saini, 1992) . These molecules w ere first 
identified during studies of inflammation (Be vi.lacqua, 1987; Shaw 
et ai, 1986; Springer et aI, 1987), and evidence indicates that 
metastasizing tumor cells usc the same adhesion pathways as 
infla mmatory cells (Rice and B evilacqua, 1989; H ession et aI, 
1990). Selectins, a group of glycoproteins that possess an N-
cerrninallectin-Iike domain (Bevilacqua and N e lson , 1993), include 
sialyl Lewis X (SL-X) and sialyl Lewis A (SL-A) , carbohydrate 
ligands for E- and P-selectin (CD62E and CD62P, respective ly) , 
fWO adhesion molecules expressed by activated endothelial cells 
(Bevilacqua and Nelson, 1993). Their relevance to cutaneous 
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bound strongly to A431 and SVK14 cells; the degree 
of binding paralleled staining intensity with CSLEX-l 
antibody. HECA-452 antibody stained A431 cells 
strongly but SVK14 cells only weakly. Nonllal kera-
tinocytes and normal epidennis did not express 
CSLEX-l or HECA-452 antigens or bind E-selectin. 
Serial sections of SCC revealed close correlation 
between fusion protein binding and antibody stain-
ing. Antibody pretreatJnent of tumor sections with 
CSLEX-l blocked fusion protein binding. whereas 
HECA-452 antibody only slightly reduced fusion pro-
tein binding. pE-sel Ig pretreated with YTl1.1 anti-
body failed to bind to A431 or SVK14 cells or to SCC. 
These studies provide functional evidence that SL-X/ 
E-selectin pathways may be important in SCC metas-
tasis and that A431 and SVK14 cells provide a good 
model to investigate these mechanisms. Key IVords: cell 
adllesiotl!fl/siotl proteitl/tl/mol' metastasis. ] II/vest Damato/ 
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tumor biology is highlighted by our recent observation that cuta-
n eous SCC ill sitll express SL-X (CD15s) but not SL-A and that 
E- selectin is present on endothelial cells adjacent to skin tumors 
(Groves cl ai, 1993). 
Studies of adhesion molecule distribution have demonstrated 
ICAM-1 on squamous cell carcinomas (SCC) but not on basa l ce ll 
carcinomas (Barker el aI , 1990). lCAM-1 is present in primary and 
metastatic melanomas (Kageshita cl aI, 1993), and an association is 
observed be tween rCAM-1 express ion and poor patient prognosis. 
Melanomas express a range of other adhesion molecules (Edward 
and Mackie, 1993) . Relatively little information erists about the 
fun ctional status of adhesion molecules on skin tumors , but some ill 
"i/l'O assays have been undertaken using soluble forms of selectin 
molecules to exam ine other types of tumors. These studies dem-
onstrated that solub le forms of E- selectin bind to colon carcinoma 
cell lines (Lobb ct aI, 1991) and that binding correlated with the 
expression ofSL-X and SL-A by these cell lines (Majuri cl aI, 1992). 
A soluble E- selectin fusion protein also demonstrated SL-X-medi-
ated adhesion of tumor cell lines (Walz el ai, 1990). E- and 
P-se lectin fusion prote ins were found to bind to tumor cell lines and 
to fi'ozen sections of human carcinoma tissue (Aruffo el aI, 199 J , 
1992). 
Several monoclonal antibodies have been used to identify car-
bohydrates related to the structure recognized by E-selectin 
(Ohmori el ai, 1993 ; Berg ct aI, 1991 a) . HECA-452 monoclonal 
antibody has been used in several studies and , like E-selectin. 
appears to recognize both SL-X and SL-A (Berg c/ ai, 1991 a) . 
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Although this antibody has also been used to define the carbohy-
drate recognized by E-selectin on skin homing lymphocytes (Be rg 
el ai, 1991b), nevertheless , HECA-452 antibody and E-selectin do 
not recognize exactly the same structures. HECA-452 does not 
label bovine (Walcheck et aI, 1993) or porcine cells (Tsang et aI, 
1995), which both bind to human E-selectin. Fusions of human 
P-selectin to human Ig have been used to study the interaction of 
P-selectin with its ligand (Aruffo et ai, 1991), although fusions of 
human E-selectin with human 19 have too low binding affinity to be 
u sed in similar studies (P. E. Stephens, personal communication). 
Fusions of the N-terminal region of E-selectin, however, from 
species such as pig (Tsang et aI, 1995), mouse, and rat (P. E. 
Stephens, personal communication) with immunoglobulin have 
binding affinities suitable for such studies. 
Keratinocyte tumor cel/lines have been used as tumor models to 
study inflammatory responses (Ferrini et aI, 1994) and tumor cell 
adhesion to extracellular matrix components (Hirano et ai, 1993) . A 
virally transformed keratinocyte cell line and spontaneously trans-
formed keratinocyte tumor cell lines express selectin ligands 
(Groves et ai, 1993), a feature which makes them potentially of 
value as ill vitro models for the study of skin tumor metastasis. We 
have used a soluble chimeric E- selectin fusion peotein (pE-sel Ig) to 
investigate binding of E- selectin to SCC in situ on frozen sections 
and to assess the suitability of keratinocyte cell lines to act as an ill 
lIityo model of metastasis for SCC. 
MATER1ALS AND METHODS 
Materials The keratinocyte cell line A431 (a human squamous carcinoma 
cell line) (ECACC, Porton Down, UK), a virally transfonned keratinocyte 
cell line (SVK14) (kind gift of Prof. I. M. Leigh; The London Hospital, 
London, UK), nonnal human keratinocytes obtained from human skin 
removed during a variety of cosmetic procedures (Groves ct ai, 1993), and 
COL0205 , a human colonic carcinoma cell line (ECACC), were grown in 
culture as monolayers as previously described (Groves e/ ai, 1993). A431, 
SVK14. and normal human keratinocytc cells were grown to approximately 
80% conflucnce and then detached from the bottom of culture flasks with 
0.25% trypsin (Gibco BRL, Paisley, UK) . Detachment of COL0205 cells 
was achieved by repeated gentle tapping on the bottom of the flask. Cells in 
suspension were washed once in their respective media and resuspended at 
a concentration of 1 X 10" cells per 1111 prior to use in binding assays. Skin 
biopsies of SCC were obtained from comenting adult patients (n :, 8). 
Tissue samples were frozen upon removal by embedding in OCT cryopro-
tectant (BOH, Poole, UK) and immersing in melting iso-pentane suspended 
in liquid nitrogen. T issue was subsequently stored in liquid nitrogen. 
111 "ilro binding assays were performed using a chimeri c fusion protein 
(pE-sel Ig) cons isting of a pig E-se lectin lectin-like domain and pig EGF-like 
domain fused to human IgG. For the construction of this fusion protein the 
lectin-like and EGF-like domains of pig E-selectin were amplified by 
polymerase chain reaction and cloned in-phase with the Fc portion of the 
human IgGl gene (Tsang eJ nl, 1995). This construct was placed down-
stream of the human cytomegalovirus promoter and expressed in C hinese 
hamster ovary cells . A biotin-conjugated version of pE-sel Ig was used for 
ill sitll binding assays. pE-scl 19 which h .. d been inactiv .. ted by blocking Witl1 
a monoclonal antibody (YT11.1) specific for the pig E-selectin lectin-like 
domain and an inelevant fusion protein (eHLT29) consisting of human Fe 
IgG fused to mouse anti-human Iymphotoxin were used in control assays. 
Immunostailling was undertaken using two antibodies, CSLEX-l (Becton 
Dickinson, Mountainview, CA) (Fukushima et ai, 1984), a mouse IgM 
monoclonal antibody that I .. bels SL-X, and HECA-452 (kind gift from Prof. 
L. J. Picker. Department of Pathology, University of Texas, Dallas, TX) 
(Duijvestijn et aI, "1988), a rat IgM monoclonal antibody that labels SL-X, 
SL-A. and the cutaneous lymphocyte antigen (thought to be a variant f0l111 
of SL-X, possibly disialyl Lewis X) (Berg et aI, 1991 b). For flow cytometry 
MECA 79 (gift from Prof. L. J. Picker) a rat IgM monoclonal antibody 
specific for mouse peripheral lymph node addressin was ll sed as an isotype 
control for HECA-452 sta ining, and Jeu 7 (Becton Dickinson) a mouse IgM 
anti-C~ 57 antibody was used as an isotypc control for CSLEX-l. A variety 
of conjugated secondary reagents was used in the binding assays and 
immunostaining including phycoerythrin-conjugated F(ab'j, goat anti-
human immunoglobulin (Jackson Immunoresearch Labs . Inc., West Grove, 
PAl, fluorescein isothiocyanate-conjugated F(ab') 2 goat 'lIlti-mouse IgM 
(Jackson lmmunoresearch), phycoerythrin-conjugated F(ab'j, goat anti-
mouse IgG (Jackson Immunoresearch). peroxidase-conjugated rabbit anti-
mouse immunoglobulins (Dako Ltd ., High Wycombe, UK), peroxidasc-
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conjugated anti-rat immunoglobulins (Dako Ltd.), and streptavidin, 
conjugated peroxidase (Amersham Ltd., Ducks., UK). 
111 Vitro Binding Assay Cells in suspension were incubated with pE-sel Ill. 
for 30 min and washed in phosphate-buffered saline containing 10% fetal 
calf serum. Bound protein was detected by incubation with phycoerytluin, 
conjugated goat anti-human Ig (Jackson Immunoresearch) fOf a further 30 
min. Controls included incubation of cells with an irrelevant fusion prote~ 
(cHLT29) and pE-sellg which had been inactivated by antibody blocking, 
Cells that bound fusion protein were quantified by flow cytometry with '\ 
FACscan (Decton Dickinson Immunocytometry Systems (BDIS), Mountain, 
View, CAl, and flow cytometry data Were analyzed with Lysis II software 
(BOIS). 
111 Situ Bi"dirrg Assay Cryostat sections (5 J.Lm) ofSCC were mounted on 
3-aminopropyltriethoxysilane-coated glass slides, air-dried, and fixed ~ 
acetone. Non-specific binding waS blocked by pretreatment of sections wit\\ 
20'Yo n0l111al swine serum in tris-buffered saline. Sections were then overlaiq 
with biotinylated fusion protein for 60 min, washed with tris-bu.ffered saline, 
and incubated with streptavidin-conjugated peroxidase (Amersham Ltd.) , 
Bound protein was then visualized by development with a substrate solutio!\ 
containing hydrogen peroxide and 3,3' -diaminobenzidine (1 mg/rnl iz\ 
tris-hnffcred saline). Sections were lightly counterstained with Mayer'l 
Haemahun and mounted in OePeX. To illVestigate the specificity of pE-se\ 
Ig binding, serial sections were incubated with either CSLEX- l or HECA, 
452 monoclonal antibodies for 60 min prior to incubation with pE-sel Ig, 
Control serial sections were incubated with antibody-inactivated pE-sel Ig, 
Immullostaillillg Comparative immunostaining was perfonned on cell 
suspensions using the monoclonal antibodies listed above and fluoresc~ 
isothiocyanate-conjugated goat anti-mouse \gM Oackson lmmunoresearch) 
or phycoerythrin-conjugated goat anti-mouse IgG 0ackson Immunore, 
search) . Labeled cells were analyzed using flow cytometry as outlined, 
above. 
Serial sections to those used for the ill sitll adhesion assay were prepared, 
as above and incubated with either CSLEX-l or l-lECA-452 antibodies fo~ 
60 min and with peroxidasc-c0l1jugated rabbit anti-mouse immunoglobuliz\ 
(Oako Ltd.) or peroxidase-conjugated anti-rat immunoglobulin (Dako 
Ltd.), respectively, for 30 min. Peroxidase development was achieved using; 
DAB as described (Groves el aI , 1993). Sections were counterstained and 
mounted as above. All experiments were performed a minimum of ti-rree 
tl01CS. 
RESULTS 
pE-sel Ig Binds to Keratinocyte Cell Lines in Vitro pE-seLIg 
bound strongly to A431 and SVK14 cells ill IJ;lro (Fig 1). Flow 
cytometry profiles for A431 cells showed a very close agreemen\ 
between cells binding pE-sel Ig and those labeled with monoclona~ 
antibodies CSLEX- l or HECA-4S2 (Fig 1). SVK14 cells were also 
labeled by CSLEX-l antibody; the flow cytometry histogram fo~ 
CSLEX-1 staining very closely resembled that obtained for pE-se\ 
19 binding. HECA- 452 antibody staining of SVK14 cells w as 
relatively weak, and considerably more cells bound pE-sel [g thall 
became stain ed with HECA-452. NHK did not bind pE-sel Ig or 
the control fusion proteins (Fig 2) and did not demonstrate 
izumunostaining. The positive control cell line , COL0205, dem_ 
onstrated a universally very high level of pE-scl Ig binding d1a\ 
closely corresponded with immunostaining results obtained with 
CSLEX-l and HECA-452 antibodies. Specificity of pE-sei 19 
binding was confirmed by the lack of binding to aU cell types of an, 
isotype-matched control protein. Furthermore, incubation of the 
E-selectin fusion protein with YT11.1, an antibody specific for the 
lectin-like domain, substantiaUy reduced the level of pE-se l III 
binding (Fig 1). Immunostaining controls using antibodies of the 
same isorype £ailed to demonstrate staining. 
pE-sel Binds to SCC ill Sit" When applied ill s;11I to frozen 
sections of SCC, pE-sel 19 bound to foci of cel.ls throughout the 
body of the tumor (Fig 3) and to isolated groups of tumor cells in 
the sunounding dermis. pE-sel Ig binding was observed in four of' 
the e ight cases of SCC examined . pE-sel [g bound to h.igh1~· 
undifferentiated areas of the tumor, and in one case it was possible 
to identify tumor cells within the lumen ofa cutaneous blood vessel 
that bound the fusion protei.n . 
Those areas of tumor that bound pE-sel Ig were stained on serial 
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Figure 1. E-seleetin fusion protein binds to ke-
ratinoeyte cell lines. A431 and SVK14 cell lines 
were incubated in suspension with either CSLEX-l or 
HECA-452 monoclonal antibodies or the E-selectin 
fusion protein . Binding of fusion protein and antibody 
staining was assessed by flow cytomctry. Histograms in 
the first column (a-g) arc the flow cytometry results 
obtained with A431 cells. and those in the second 
column arc results obtained with SVK14 cells (ii-II) . In 
each case results are representative of data collected 
from four or more assays with MECA-79 antibody (a, 
iI) , HECA-452 antibody (b, ')' leu 7 antibody (c, J). 
CSLEX-l antibody (d, k). C HLT29 fusion protein (e, 
I). pE-sel Ig fusion protein if, III) , and pE-sel Ig 
pretreated with YT11.1 antibody (g, II ). 
~1 k 
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sections with HECA-452 and CSLEX-l monoclona l an tibodies 
(Fig 3) . T h e patte rn ofHECA-452 staining c losely corresponded to 
tb e areas of tumor w hich bound pE-sel Ig. T he CSLEX-l antibody 
also stained the areas of tumor th at bo und E-selectin and in addition 
stained other areas of tumor that did not bind pE-sel Ig and were 
no t stained by HECA-452 an tibody. M any in fi ltratin g cells sur-
roundin g tumors demonstrated low levels of binding with the 
fus ion protein reflecting the cell surfa ce expressio n of HECA-452 
an d CSLEX-'I epito pes by these cells. Peri lesio nal n o rmal skin 
sbowed no binding of pE-sel Ig, and an tibo dy staining was re-
stricted to Langerhans cells w ithin the epidermis, as previously 
described (Ross e/ ai, 1994). On serial sectio ns, pE-scl Ig binding to 
SCC was almost co mpletely blocked by pretreating the tissue with 
CSLEX-1 monoclo n al antibody (Fig 3), and preincubation of tissue 
sections w ith HECA-452 antibody produced o nly a slig ht redu ction 
in pE-sel 19 adhesion . As with the ill "itro resu lts, control proteins 
failed to demonstrate binding. 
DISCUSSION 
In this study we h ave demonstrated that a fusion protein containing 
a terminal E- selectin lectin-like d om ain binds to both cutaneous 
SCC tllmor cells ill sitll and to keratinocyte cell lin es ;11 ,,;Iro. 
Previous studies h ave shown that E- selectin expressed by cytokine-
activated endothe lial cells during inflammation binds SL- X, SL-A, 
and cutaneous lymphocyte antigen epitopes expressed by n eu tro-
phils, m o nocytes, and a subpopula tion of skin-homing lymphocytes 
(Bevilacqua and N elson , 1993; Pickel' et ai, 1991). We have shown 
that the sam e areas of cutaneolls SCC to wh.ich the E-selectin fusion 
protein binds also strongly express SL- X and cutaneous lymphocyte 
antigen epitopes and that antibodies to these epitopes block E-
614 ALLEN fiT AL 
Figure 2. NHK did not bind pE-sel Ig. NHK \Vere incubated LInder the 
same conditions used for keratinocytc cell lines with pE-scl /g (II), CHL T29 
conttol fllsion protein (b), and pE-scl Ig pretreated with YT11.1 antibody (c). 
selectin adhcsio n. These results indicate that see express func-
tional ca rbohydrate ligands capable of binding E-seJectin. Although 
E-selcctin is known to be all adhesio n molecule involved in in-
flammatory adhesion mechanisms (Bevilacqlla and Nelson, 1993; 
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Sprillger, 1990), it is widely hypothesized that tumor cells may also 
exp loit the same adhesion pathways as a means of m ctastasis 
(Bevilacqua and Nelson, 1993; Keelan and Haskard, 1992). Thus 
tumo)· cells expressing E-selectin ligands may be able to use 
E-selecti.n, which we have previously demonstrated to be widely 
expre;ssed on endothelial cells adjacent to see aud basal cell 
carCil'lOl11a S (Groves e( ai, 1993), as a means of migratiJlg into the 
vascular or possibly lymphatic systems and subsequently em erging 
at sites of secondary tumor formation. Thc correlation between 
metas tatic potential and E-selectin adhesion is further supponed by 
our previous finding that basal cell carcinomas, which have a low 
metas tatic potenti'll and normal skin, express low or zero levels of 
E-sel ectin ligands (Groves el ai, 1993). We have now confirmed 
that ~eratinocytes in normal skin, perilesional to see, do not show 
binding with the E-selectin fusion protein. 
Pt"evious studies have shown that the degree of expression o~ 
carbohydrate antigens including E-selectin ligands in a variety Ot' 
tumors m ay be related to disease progression and that the expres-
sion of cell surface carbohydrates distinguishes mctastatic deposits 
fi-ot'l1 primary tumor; in particular, metastatic deposits of colon 
carcinoma have been found to express higher levels of SL-X than 
primary tumor (Hakolllori, 1991). Sawada et ai, (1994), when 
comparing tUlllor cells of different m etastatic potential, also found 
clutt j']ighly m etastatic colon carcinoma celJs cxpressed more SL-X 
than did cells of low metastatic potential ilJJd adhered in greater 
numbers (0 E- selectin-expressing ceUs. 
Keratinocyte cell Jin e expression of functional E-sclectin ligand 
iJldic :ltes that these cells may rep resent an attractive ;/1 ,';(m model 
wi th which to study see metastasis. T h e d·evelopment of an ill ";f.ro 
model for skin tUJ110r m etastasis has a number of important 
impli cations. In this study and jn several previous investigations, it 
Figure 3. pE-sei Ig binds to frozen sections of sec. Serial cryostnt sections of SCC were incubated with pE-sel Ig fusion protein (n), CSLEX- l (b). 
and HECA-452 monoclona) antibodies (c). On a further serial section (d) , tissue was pJ:eincubatcd with CSLEX-l antibody prior to application ofpE-sellg. 
Sc,'/c bar = 100 Mill . 
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has been shown that the E-selectin / ligand intera ction !nay be 
effectively blocked by monoclonal antibodies. Using an ill IIil ro 
binding assay m ay be an efFective m ethod of investigating antibody 
blocking as a means of improving tumor th erapy. T he introduction 
of soluble forms of E-selectin o r carbo hydrate molecules to com-
petitively inhibit selectin/ ligand interaction may also prove fruitfu l 
as a m ean s of tumor the rapy. 
Our observation, ill II ilro , that both A431 and SVK14 cells bind 
pE-sel 19 and stain w ith CSLEX-l antibody, whereas HECA-452 
antibody stains A431 cells strongly and SVKt4 cells only very 
weakJy, suggest that for these ce lls, CSLEX-l antibody is a better 
marker for E-sclectin binding abil ity. Correspondingly, CSLEX-l 
antibody demonstrated a much greater capacity than did HECA-
452 antibody to block E-selectin binding to SCC ill sit ll . Thus, the 
ill sitll use of the E-selectin binding assay may in itself be a useful 
diagnostic tool , in conjun ctio n with antibody sta ining, to predict 
likely m etastatic poten tiaL 
In conclusion , we have demonstrated that tumor cell s ill si lll 
possess fWlCtio nal adhesion molecules. Th is evidence supports the 
hypothesis that m etastasizin g tumor cells utitize the same adh esion 
pathways as those currently being inves tigated for inflamll1atory 
cells. We propose the li se of keratinocyte cell lines as a useful i/l. 
IIitro model fo r the study of these m echanisms of m etastasis. 
This work II 'as ill pari SIIpporled by (/ gra ll/ ji-O/ll Dllllhill Medical T,."sl. 
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